MedTrace Logo

Retrospective Pathology Foundation Models

NCT07239297 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-11-20

No results posted yet for this study

Summary

By integrating retrospective multimodal data such as pathology and imaging, AI technologies offer novel solutions for disease classification, tumor grading, histological and molecular subtyping, selection of chemotherapy regimens, risk stratification, and treatment-response prediction. This research direction not only deepens our understanding of tumor biological characteristics but also provides essential support for precision medicine and individualized therapy. It holds significant theoretical and practical value and has important implications for mitigating strained medical resources and improving the accuracy of therapeutic decision-making, representing a cutting-edge application with substantial translational potential.

Conditions

  • Pancancer

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Li Liang · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2027-07-31
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07239297 on ClinicalTrials.gov